Foresight diagnostics and QIAGEN announce strategic partnership to advance development of companion diagnostic kits for lymphoma
June 6, 2025
Foresight Diagnostics announced a strategic, worldwide partnership with QIAGEN to develop and commercialize a kit-based version of Foresight’s CLARITY assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies.
Together, the companies aim to lay the groundwork for a standardized, regulated diagnostic kit that, once validated and approved in pharmaceutical-sponsored trials, would be the only circulating tumor DNA (ctDNA)-based MRD assay available as both a central laboratory service and diagnostic kit capable of supporting clinical decision-making and therapeutic strategies for patients with hematological cancers.
